Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 12, 2016, Pages 1319-1329

  Campos Varela, I ^a,b,c   Moreno, A ^d   Morbey, A ^e   Guaraldi, G ^f   Hasson, H ^g   Bhamidimarri, K R ^h   Castells, L ^i,j   Grewal, P ^k   Banos I ^l   Bellot, P ^i,m   Brainard, D M ⁿ   McHutchison, J G ⁿ   Terrault, N A ^c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁿ GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; BOCEPREVIR; DACLATASVIR; EMTRICITABINE; INTERFERON; LEDIPASVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; TENOFOVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; LIFE EXPECTANCY; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MALE; MIXED INFECTION; PHOTOSENSITIVITY; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; COINFECTION; COMBINATION DRUG THERAPY; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; HIV INFECTIONS; LIVER CIRRHOSIS; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; INTERFERONS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84964345859     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13629     Document Type: Article

References (23)

1. Terrault NA, Roland ME, Schiano T, et al,. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-26.
2. Miro JM, Montejo M, Castells L, et al,. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012; 12: 1866-76.
3. Terrault N, Reddy KR, Poordad F, et al,. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients. Am J Transplant 2014; 14: 1129-35.
4. Castells L, Rimola A, Manzardo C, et al,. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J Hepatol 2015; 62: 92-100.
5. Burton JR Jr, O'Leary JG, Verna EC, et al,. A US multicenter study of hepatitis c treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61: 508-14.
6. Coilly A, Furlan V, Roche B, et al,. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56: 5728-34.
7. Forns X, Charlton M, Denning J, et al,. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-94.
8. Charlton M, Gane E, Manns MP, et al,. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17.
9. Saab S, Greenberg A, Li E, et al,. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int 2015; 35: 2442-7.
10. Gutierrez JA, Carrion AF, Avalos D, et al,. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transplant 2015; 21: 823-30.
11. Leroy V, Dumortier J, Coilly A, et al,. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; 13: 1993-2001 e2.
12. Kwo PY, Mantry PS, Coakley E, et al,. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-82.
13. Campos-Varela I, Straley S, Agudelo EZ, Carlson L, Terrault NA,. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transplant 2015; 21: 272-4.
14. Antonini TM, Furlan V, Teicher E, et al,. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. Aids 2015; 29: 53-8.
15. Wiesner RH, Sorrell M, Villamil F, International Liver Transplantation Society Expert P. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.
16. Campos-Varela I, Peters MG, Terrault NA,. Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting. Clin Infect Dis 2015; 60: 108-16.
17. Janssen Therapeutics. Simeprevir [package insert]. Titus-ville, NJ: Janssen Therapeutics, 2015.
18. El-Sherif O, Khoo S, Solas C,. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS 2015; 10: 348-54.
19. Gilead Sciences. Sofosbuvir [package insert]. Foster City, CA: Gilead Sciences, 2015.
20. Rodriguez-Torres M, Gaggar A, Shen G, et al,. Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. J Acquir Immune Defic Syndr 2015; 68: 543-9.
21. Molina JM, Orkin C, Iser DM, et al,. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385: 1098-106.
22. Badri P, Dutta S, Coakley E, et al,. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015; 15: 1313-22.
23. Pellicelli AM, Montalbano M, Lionetti R, et al,. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46: 923-7.